APR 16, 2015 9:27 AM PDT

Tumor-Only Genetic Sequencing May Mislead Cancer Therapy

WRITTEN BY: Ilene Schneider
When it comes to sequencing patients' tumor genomes to personalize cancer therapy, one very important step may be missing, suggest Johns Hopkins researchers: a point of comparison to patients' noncancerous genomes.
Johns Hopkins researchers cite the importance of comparing patients' cancerous and noncancerous genomes.
Without these comparisons - or a full picture of a patient's genome - nearly half of all patients may be getting the wrong cancer treatment, say the researchers at the John Hopkins Kimmel Cancer Center.

"By not sequencing each person's normal tissue to filter out noncancer-related changes, it's difficult to really understand what is occurring in the tumor," said Victor Velculescu, M.D., Ph.D., a professor of oncology and pathology and co-director of the Cancer Biology Program at the Johns Hopkins University School of Medicine, in a press release.

The study appears today in Science Translational Medicine.

When Velculescu and colleagues compared the genomes of tumor and normal tissue from more than 800 cancer patients' sequencing data, they found that approximately 65 percent of the genetic changes identified with tumor-only genetic sequencing were "false positives" and not related to the patient's cancer. That's because, by first sequencing a patient's noncancer genome, the researchers identified which genetic changes are heritable variations.

The researchers also looked at changes in "actionable genes," or genes for which some drug or therapy has been identified. In this case, false positive affected 48 percent of the patients analyzed.

"In tumor-only analyses, we found that nearly half of patients had tumor mutations that were actually germline or false positives in actionable genes, and they could lead to inappropriate therapy," Velculescu said.

Inaccurate genetic information can lead to side effects from incorrect targeted therapies and increased costs of patient care from misdirected medicines, report the researchers.

That said, Velculescu and his team acknowledge the challenges associated with implementing tumor-normal analyses in a clinical setting - including added costs of sequencing a patient's normal tissue.

These study results build on the concept of precision medicine, in which oncology researchers hope that one day, DNA sequencing will be a reality for every cancer patient, so that patients may receive personalized therapy.

By Stephanie Guzowski, Editor, Drug Discovery News
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 02, 2020
Cancer
MAR 02, 2020
E. coli and colon cancer
Research published recently in Nature provides evidence for a direct link between the presence of E. coli and ...
MAR 28, 2020
Cancer
MAR 28, 2020
The Not So Minor Genetic Players in Head and Neck Cancers
Head and neck squamous cell carcinomas (HNSCC) are among the most prevalent cancers among smokers, linked to alcohol con ...
APR 16, 2020
Cancer
APR 16, 2020
This drug hopes to prevent cancer relapse
A report published in Nature Communications highlights findings from a study showing that the experimental drug, Qu ...
APR 21, 2020
Clinical & Molecular DX
APR 21, 2020
Skin Deep: Handheld Device Sees the Earliest Signs of Cancer
Researchers have developed a handheld device that can image structures under the skin at resolutions 100 times greater t ...
APR 23, 2020
Cancer
APR 23, 2020
Doctors, watch out for unexpected side effects in small clinical trials
Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpe ...
APR 25, 2020
Cancer
APR 25, 2020
Breaking the Blood-Brain Barrier in the Fight Against Brain Cancer
One of the more unique aspects of the human body is the blood-brain barrier (BBB) that protects the central nervous syst ...
Loading Comments...